<DOC>
	<DOCNO>NCT01492491</DOCNO>
	<brief_summary>The purpose study evaluate serum concentration antoxidant vitamines A , C , E , inflammatory cytokine middle-large toxin patient treat online hemodiafiltration , standard HFR SUPRA-HFR .</brief_summary>
	<brief_title>Collaborative Research HFR High Flux</brief_title>
	<detailed_description>Today , research work EUTOX group highlight , large cytokine protein-bound solute gain relevant attention emerge role mortality predictor . Online hemodiafiltration ( online HDF ) demonstrate offer significant depuration small middle toxin , removal protein-bound solute scarce . Synthetic high-flux membrane allow infact significant removal molecule heavier 15-20 KDa . Super-flux membrane may enhance online HDF convective transport would surely expose patient unacceptable loss albumin , vitamines aminoacids non selectivity convective transport . HFR renal replacement therapy utilizes convection , diffusion adsorption . It use double-stage filter consist high-flux polyethersulfone hemofilter first convective stage low-flux polyethersulfone filter second diffusive stage . The stage filter allow complete separation convection diffusion . The convective part first stage allow pure ultrafiltrate ( UF ) pas sorbent resin cartridge . The first convective/adsorption stage net fluid removal . The blood reinfused clean UF undergo traditional dialysis . The second stage work classicaHD final stage weight loss occur . HFR demonstrate various clinical trial reduce microinflammatory state albumin loss minimal aminoacids loss , thanks high selectivity resin sorbent . SUPRA-HFR newly develop HDF therapy base HFR concept scheme , include super-flux membrane first section , couple empower resin sorbent . This significantly enhance large solute depuration , overcome online HDF flaw . Therefore propose prospective , multicenter , randomize study compare online HDF , standard HFR SUPRA-HFR . After wash-out stabilization period 4 month post-dilution online HDF , expect number 50 patient randomize either standard HFR ( 25 ) SUPRA-HFR ( 25 ) follow 6 month . Primary end point focus removal protein-bound solute , inflammation nutritional state . In addition , ESAs dose hemoglobin level assess compare treatment group . This study provide strong evidence safe clinically effective use super-flux membrane , introduce SUPRA-HFR therapy . It highly likely outcome study affect daily clinical practice Italian European dialysis center potential innovation bring market . The following hypothesis test : - SUPRA-HFR selectivity reduce consistently albumin , aminoacids vitamines A , C , E loss compare online HDF . - SUPRA-HFR good preservation nutritional parameter , couple possibility remove protein-bound toxin cytokine lead high reduction microinflammatory status , compare online HDF standard HFR . - SUPRA-HFR impact inflammation status ameliorate anemia management reduce administer ESAs dos .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>dialysis vintage &gt; 6 month well function vascular access ( QB &gt; 300 mL/min ) inform consent give polycystic kidney disease ( PKD ) significant acute chronic inflammatory comorbidities nonrenal related anemia blood transfusion last 2 month enrollment alcohol drug abuse malignant neoplasm hemoglobinopathy myelopathy pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>SUPRA-HFR</keyword>
	<keyword>adsorpition</keyword>
	<keyword>vitamin</keyword>
	<keyword>large toxin</keyword>
</DOC>